MANKIND vs WANBURY: Stock Comparison
MANKIND PHARMA is the larger company by market capitalisation. MANKIND PHARMA shows faster revenue growth, lower leverage and a higher net margin, while WANBURY shows a lower P/E, a higher ROE and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
MANKIND leads 6; WANBURY leads 4 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | MANKIND | WANBURY |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | MANKIND | WANBURY |
|---|---|---|
| Live Price | ₹2,486 | ₹178.5 |
| Day Change | 0.68% | -1.89% |
| Volume | 33,312 | 4,556 |
| 52-Week High | ₹2,642 | ₹358.85 |
| 52-Week Low | ₹1,909.7 | ₹161.5 |
| Distance from 52W High | -5.9% | -50.26% |
Valuation
| Metric | MANKIND | WANBURY |
|---|---|---|
| Market Cap | ₹1.02 L Cr | ₹649 Cr |
| P/E Ratio | 45.19x | 0x |
| P/B Ratio | 5.78x | 0x |
| EPS | ₹13.9 | ₹4.1 |
| Book Value | ₹401 | ₹43.94 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | MANKIND | WANBURY |
|---|---|---|
| Revenue Growth (TTM YoY) | 11.8% | -19.2% |
| EPS Growth (TTM YoY) | 31.7% | 0% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | MANKIND | WANBURY |
|---|---|---|
| ROE | 11.7% | 45.78% |
| ROCE | 10.93% | 25.06% |
| Net Margin | 13.34% | 10.17% |
| Operating Margin | 20.73% | 13.81% |
| Debt to Equity | 0.38x | 1.49x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | MANKIND | WANBURY |
|---|---|---|
| Promoter Holding | 72.62%▼ 0.01 pp | 34.33%▼ 0.03 pp |
| FII Holding | 9.37%▼ 0.08 pp | 0.71%▼ 0.18 pp |
| DII Holding | 15.56%▲ 0.17 pp | 0.02%▼ 0.04 pp |
| Public Holding | 2.45%▼ 0.08 pp | 56.28%▲ 0.25 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: MANKIND PHARMA and WANBURY.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.